digest
Short Summary
Main recommendation: Dr. Spencer Nadolsky argues that tirzepatide should not yet be recommended for most adults, especially those without overweight or obesity, because evidence in that group is lacking, though he sees future potential for broader use. He critiques Dr. Mike Israetel's claim that most adults should consider taking tirzepatide even if not overweight, while steelmanning the argument by discussing clinical obesity and possible off-label effects.
Key Points
- The core objection is the mismatch between "evidence-based" and recommending the drug for people who are not overweight, since phase three trials of tirzepatide enrolled people with type 2 diabetes or overweight/obesity.
- Nadolsky's steelman notes that "most" adults in the US have overweight or obesity, and that clinical obesity (harm from excess fat despite a normal BMI) can extend benefit to some people with a normal BMI.
- He reports anecdotal, clinic-based observations of reduced alcohol use, lower binge eating interest, improved PCOS cycles, and improved symptoms in autoimmune inflammatory disorders, but notes these need randomized trials.
- He suggests future primary and secondary cardiovascular prevention, prevention of obesity in people with strong family histories, and use in lean individuals, while stressing these remain hypotheses.
- He does not recommend the drug for lean, healthy people without an indication and says he does not take it himself.
Details Worth Noting
- Concrete instructions: The video gives no step-by-step dosing or preparation instructions. The only actionable guidance is to discuss off-label use with your doctor, not to use these medicines without a proper indication, and to be aware that lean individuals would likely need sub-therapeutic doses whose benefit is unknown.
- BMI definition given: overweight is a BMI of 25 to just under 30 kg/m².
- Off-label context: tirzepatide (Mounjaro) was approved only for type 2 diabetes when early obesity use began, and clinic experience preceded formal trials.
- The only randomized trial mentioned for alcohol use involved a low dose of semaglutide, not tirzepatide.
- Nadolsky describes tirzepatide as more powerful, in his clinical experience, than SSRIs, topiramate, and Vyvanse for binge eating disorder, and says studies are ongoing.
- He notes he has Hashimoto's and might theoretically benefit, but currently has no indication.
Bottom Line
Tirzepatide's broader benefits, such as for alcohol use, PCOS, autoimmune disease, or heart disease prevention in lean people, remain promising but unproven, so the evidence needs to catch up before most people are recommended the drug.
